Blog

In a distressing turn of events, Dr. Anna Nusslock, a 36-year-old chiropractor from Eureka, California, was faced with a critical medical situation that brought unexpected legal and ethical challenges to the forefront. In February, Dr Nusslock, who was pregnant with twins, suffered a premature rupture of membranes at 15 weeks' gestation. Medical assessments indicated that the survival of her twins was highly unlikely and that continuing the pregnancy posed serious risks to her health, including potential infections and significant blood loss. Despite the urgent medical recommendation for an abortion given the non-viability of the fetuses and the health risks involved,…

A pharmaceutical company's attempt to win approval for a new Alzheimer's treatment, simufilam, continues amid a flurry of controversy and regulatory challenges. Recent investigations have cast doubt on the basic studies supporting simufilam. These concerns increased when scientific journals retracted several studies and key figures at Cassava Sciences, the drug's sponsor, resigned. Despite these setbacks, in September the Securities and Exchange Commission (SEC) accused Cassava Sciences of disseminating misleading data about their clinical trials. However, the company settled these charges by paying $40 million, without admitting any guilt. Interestingly, simufilam is still undergoing Phase 3 trials, involving more than 1,900…